X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3023) 3023
Publication (475) 475
Newsletter (36) 36
Book Review (25) 25
Magazine Article (9) 9
Book Chapter (8) 8
Dissertation (7) 7
Newspaper Article (6) 6
Conference Proceeding (4) 4
Data Set (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2153) 2153
lopinavir (1866) 1866
hiv infections - drug therapy (1614) 1614
index medicus (1365) 1365
infectious diseases (1252) 1252
male (1242) 1242
female (1223) 1223
adult (1087) 1087
ritonavir (909) 909
hiv (889) 889
pharmacology & pharmacy (783) 783
ritonavir - therapeutic use (743) 743
middle aged (711) 711
antiretroviral therapy (677) 677
lopinavir/ritonavir (676) 676
immunology (659) 659
protease inhibitors (653) 653
hiv protease inhibitors - therapeutic use (636) 636
anti-hiv agents - therapeutic use (620) 620
ritonavir - administration & dosage (546) 546
hiv infections - virology (535) 535
pyrimidinones - therapeutic use (535) 535
virology (498) 498
drug therapy, combination (495) 495
viral load (492) 492
treatment outcome (450) 450
microbiology (432) 432
antiviral agents (413) 413
hiv-1 - drug effects (409) 409
pharmacokinetics (409) 409
anti-hiv agents - administration & dosage (391) 391
hiv protease inhibitors - administration & dosage (389) 389
drug therapy (378) 378
ritonavir - adverse effects (375) 375
pyrimidinones - administration & dosage (357) 357
therapy (350) 350
hiv infection (347) 347
human immunodeficiency virus--hiv (346) 346
cd4 lymphocyte count (338) 338
hiv protease inhibitors - adverse effects (330) 330
antiretroviral drugs (319) 319
drug combinations (305) 305
efavirenz (303) 303
lopinavir - therapeutic use (301) 301
highly active antiretroviral therapy (300) 300
tenofovir (290) 290
hiv-1 (289) 289
anti-hiv agents - adverse effects (285) 285
antiretroviral therapy, highly active (283) 283
aids/hiv (275) 275
ritonavir - pharmacokinetics (268) 268
pyrimidinones - adverse effects (267) 267
efficacy (257) 257
drug interactions (252) 252
atazanavir sulfate (251) 251
research (250) 250
safety (250) 250
hiv protease inhibitors - pharmacokinetics (247) 247
atazanavir (245) 245
aids (244) 244
adolescent (243) 243
health aspects (237) 237
hiv protease inhibitors - pharmacology (233) 233
virus diseases (228) 228
young adult (226) 226
article (224) 224
protease inhibitor (224) 224
dosage and administration (222) 222
drug administration schedule (216) 216
anti-hiv agents - pharmacokinetics (215) 215
hiv-1 - genetics (215) 215
pyrimidinones - pharmacokinetics (209) 209
analysis (207) 207
lopinavir - administration & dosage (203) 203
nevirapine (203) 203
darunavir (200) 200
risk factors (198) 198
ritonavir - pharmacology (194) 194
proteases (193) 193
human-immunodeficiency-virus (192) 192
hiv infections - blood (189) 189
hiv-1-infected patients (189) 189
nelfinavir (188) 188
active antiretroviral therapy (187) 187
hiv infections - complications (186) 186
infection (186) 186
lamivudine (185) 185
rna, viral - blood (185) 185
prospective studies (183) 183
hiv-infected patients (180) 180
reverse transcriptase inhibitors - therapeutic use (179) 179
saquinavir (179) 179
combination (178) 178
aged (177) 177
drug resistance, viral (169) 169
mutation (169) 169
resistance (169) 169
pregnancy (168) 168
animals (166) 166
pyrimidinones - pharmacology (166) 166
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2906) 2906
Spanish (103) 103
German (33) 33
French (21) 21
Russian (10) 10
Japanese (8) 8
Chinese (3) 3
Italian (3) 3
Portuguese (3) 3
Czech (1) 1
Serbian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Pediatric Infectious Disease Journal, ISSN 0891-3668, 2014, Volume 33, Issue 3, pp. 301 - 305
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2014, Volume 69, Issue 5, pp. 1390 - 1396
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, p. e0171611
Objective The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (Pl/r-MT) with... 
GLOMERULAR-FILTRATION-RATE | REVERSE-TRANSCRIPTASE INHIBITORS | EFFECTIVE ANTIRETROVIRAL THERAPY | MYOCARDIAL-INFARCTION | MULTIDISCIPLINARY SCIENCES | PROTEASE INHIBITOR MONOTHERAPY | LOPINAVIR-RITONAVIR MONOTHERAPY | INCOMPLETE REVERSIBILITY | MONET TRIAL | HIV-1-INFECTED PATIENTS | COHORT COLLABORATION | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Male | HIV - drug effects | Viral Load | Young Adult | RNA, Viral - genetics | Ritonavir - therapeutic use | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Drug Therapy, Combination | HIV Infections - virology | Kaplan-Meier Estimate | Proportional Hazards Models | Viremia - genetics | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | Outcome Assessment (Health Care) - statistics & numerical data | HIV - genetics | HIV Infections - drug therapy | Lopinavir - therapeutic use | Viremia - blood | Darunavir - therapeutic use | Cohort Studies | Antiviral agents | RNA | Ritonavir | Analysis | Dosage and administration | Research | HIV infection | Antiretroviral drugs | Therapy | Viremia | Lopinavir | Regression analysis | Criteria | Ribonucleic acid--RNA | Medical diagnosis | Patients | Reintroduction | Data bases | CD4 antigen | Studies | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Hemoglobin | Data collection | Drug therapy | Failure | Deoxyribonucleic acid--DNA | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Ribonucleic acid | AIDS | HIV | DNA | Human immunodeficiency virus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1726 - 1737
In this randomized, controlled trial in Africa and India, combination antiretroviral therapy was more effective than standard therapy in preventing... 
PRETERM DELIVERY | CHILD-MORTALITY | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | INFECTED WOMEN | PROGESTERONE LEVELS | ADVERSE BIRTH OUTCOMES | LOPINAVIR/RITONAVIR | LOPINAVIR EXPOSURE | PROTEASE | PREGNANCY | HIV Infections - prevention & control | Infant Mortality | Humans | African Americans | Perinatal Care | Infant | Young Adult | Adult | Female | HIV Infections - transmission | Drug Therapy, Combination | Infant, Newborn | Infant, Low Birth Weight | Anti-Retroviral Agents - therapeutic use | Tenofovir - therapeutic use | Zidovudine - adverse effects | Anti-Retroviral Agents - adverse effects | CD4 Lymphocyte Count | Gestational Age | Pregnancy | Infant, Premature | Zidovudine - therapeutic use | HIV Infections - ethnology | Nevirapine - administration & dosage | Infectious Disease Transmission, Vertical - prevention & control | Pregnancy Outcome | Prevention | Highly active antiretroviral therapy | Complications and side effects | Care and treatment | Nevirapine | Pregnant women | HIV patients | Dosage and administration | Research | HIV (Viruses) | Zidovudine | Health aspects | Emtricitabine | Neonates | Antiretroviral drugs | Breastfeeding & lactation | Ritonavir | Lopinavir | Lamivudine | Infants | Gestation | Antiretroviral therapy | Postpartum | CD4 antigen | Disease prevention | Tenofovir | Cost-benefit analysis | Disease transmission | Maternal & child health | Human immunodeficiency virus--HIV | Birth weight | Drug therapy
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 04/2015, Volume 29, Issue 7, pp. 825 - 830
Journal Article